SINOMED(SH:688108) Shang Hai Zheng Quan Bao·2025-08-13 18:21Core Viewpoint - The stock of Sino Medical Science Technology Co., Ltd. has experienced significant abnormal trading fluctuations, with a cumulative closing price increase of 100% over five consecutive trading days from August 7 to August 13, 2025, and a 30% increase over three consecutive trading days from August 11 to August 13, 2025 [2][6]. Trading Abnormalities - The company's stock trading has been classified as experiencing severe abnormal fluctuations according to the Shanghai Stock Exchange's trading rules [2][6]. - As of August 13, 2025, the closing price of the company's stock was 29.50 yuan per share, which has seen a substantial increase compared to most of its industry peers and the Shanghai Composite Index [4][11]. Company Disclosures - The company conducted a self-examination and confirmed that its daily operations are normal, and there have been no significant changes in market conditions or industry policies [3][7]. - The company has disclosed several key announcements, including the conditional approval of a new drug-eluting stent system by the FDA on July 22, 2025, and the forecast of its half-year performance on July 25, 2025 [3][8]. FDA Breakthrough Device Designation - The company's subsidiary has received FDA breakthrough device designation for its COMETIU self-expanding intracranial drug-coated stent system and COMEX balloon microcatheter, which allows for expedited development and review processes [5][13]. - This designation does not guarantee that the products will receive FDA market approval, as they must still meet various regulatory requirements [14]. Stock Performance Metrics - The company's rolling price-to-earnings (P/E) ratio is reported at 1701.41, significantly deviating from the industry average P/E ratio of 33.59 for specialized equipment manufacturing [4][11]. - The trading turnover rates from August 7 to August 13, 2025, were notably high, indicating increased trading activity compared to previous periods [4][13].